Description

Corcept Therapeutics: The $2 Billion Endocrinology Target Needs Broader Screening Adoption!

Corcept Therapeutics reported first quarter 2026 revenue of $164.9 million, marking a modest increase from $157.2 million in the same period last year. The company raised its 2026 revenue guidance to a range of $950 million to $1.05 billion. Despite the top-line growth, Corcept recorded a net loss of $31.8 million in the quarter compared to net income of $20.5 million in the first quarter of 2025. The company held $515 million in cash and investments as of March 31, 2026. Demand for Corcept’s endocrinology medications, particularly those targeting hypercortisolism and Cushing’s syndrome, remains robust, with record new prescriptions and prescriber counts reported. However, the full revenue impact is delayed by several factors: typical first-quarter dips due to insurance prior authorization procedures, lower initial revenue from new patients before dose titration and payer coverage stabilization, and the ongoing backlog in insurance prior authorizations amid a pharmacy vendor transition.